UroGen Pharma Ltd. (URGN) has announced the pricing of its underwritten public offering, consisting of 5 million ordinary shares set at $17.50 each. Additionally, to certain investors, in place of ordinary shares, the company will issue pre-funded warrants to purchase 1.14 million ordinary shares at a price of $17.499 per warrant (aligning with the public offering price minus a $0.001 exercise price per warrant).
The company anticipates gross proceeds of approximately $107.5 million from this offering, prior to deductions for underwriting discounts, commissions, and estimated offering expenses.
Furthermore, UroGen has provided the underwriters with a 30-day option to acquire up to an additional 921,428 ordinary shares at the public offering price, deducting underwriting discounts and commissions.
The offering's closure is anticipated on June 20, 2024.
